NEMIS secures CHF 3.4 million in Series B round


This year, NEMIS Technologies plans to launch its first diagnostic kits for bacterial detection in food and healthcare fields. This ambition will be funded by the 3.5 million Swiss francs raised in a Series B round. 


Established in 2018, NEMIS Technologies develops rapid, simple, on-site/point-of-care and low-cost diagnostic test kits based on the company’s AquaSpark, a novel platform technology consisting of synthetic molecules designed to detect live bacteria using chemiluminescence (production of light from a chemical reaction) in a shorter time frame compared to conventional solutions that required 48 hours or more. 

The diagnostic kit allows for detecting pathogenic bacteria across a wide range of applications such as the food chain in the fields of animal health, environmental monitoring, food and beverage production and for the healthcare system for clinical diagnostics and hospital hygiene. The startup is also planning a proof-of-concept to bring its technology to the water safety testing market

One year following the closing of its seed round, the startup announced the receipt of additional CHF 3.4 million from undisclosed investors. The funds will allow the company to advance its pipeline and prepare the market launch of its first diagnostic kits in 2020 focusing on the food safety market to detect Salmonella, Listeria monocytogenes, E. coli, coliforms and Listeria spp. 

In line with the announcement, NEMIS has also announced a Seed B extension round to raise an additional CHF 1.7M.